AHCY inhibitors cause growth inhibition of prostate cancer via induction of mir-26a

Noriko Uchiyama1 and Tomohiro Kawamoto2
1Takeda Pharmaceuticals International Co., Boston, USA
2Takeda Pharmaceutical Company Limited, Kanagawa, Japan

Most prostate cancers initially respond to androgen deprivation therapy, but then progress from androgen-dependent to androgen-independent prostate cancers. In the present study, a differential cytotoxicity screen of hormone-resistant prostate cancer LNCaP-hr cells and the parental LNCaP-FGC cells against normal MRC5 fibroblast cells, identified a small molecule compound, Aristeromycin (a derivative of 3-deazaneplanocin A (DZNeP)). The molecular target was shown to be S-adenosylhomocysteine hydrolase (AHCY), which catalyzes reversible hydrolysis of S-adenosylhomocysteine (SAH) to adenosine and L-homocysteine. DZNeP and Aristeromycin showed high inhibitory activity against AHCY. Treatment of the prostate cancer cells with DZNeP led to SAH accumulation and decreased levels of homocysteine and histone H3K27 methylation. SAH accumulation and cell growth inhibition were confirmed after siRNA-mediated AHCY knockdown. To further understand why AHCY inhibitors decreased prostate cancer cell growth, we performed microRNA expression profiling with LNCaP-hr cells. Mir-26a, which is involved in regulation of EZH2 expression, was upregulated in Aristeromycin-treated LNCaP-hr cells. A reporter assay established with the EZH2 3α-UTR confirmed that transfection of microRNA precursor molecules for miR-26a decreased the EZH2 3α-UTR luciferase activity. Meanwhile, an antisense microRNA inhibitor for miR-26a recovered the luciferase activity. The present findings suggest, at least in part, that miR-26a induced by an AHCY inhibitor can regulate oncogenic EZH2 expression, and could thus be an important mechanism of action for AHCY inhibitors in the treatment of prostate cancer.

Biography

Noriko Uchiyama is a Researcher of Investigative Toxicology of Drug Safety Research Evaluation, Takeda Pharmaceuticals International Co. Her work is devoted to the cutting-edge biotechnologies to identify, understand and de-risk toxicities in Takeda’s next generation of medicines. The team develops and validates predictive in-vitro models of toxicology for use in early compound screening to estimate risk of a specific toxicity. Other topics of her work are the drug discovery process e.g. establishment of in-vitro assay system of enzyme and cell-based assay, screening and evaluation of compounds, narrowing good chemotypes in the drug discovery projects. Her expertise is cell pharmacology in the Oncology therapeutic target including kinase, protease, nuclear-receptor, channel etc. She is involved in drug discovery for novel drugs from both perspectives i.e. in-vitro mechanistic investigation of efficacy of targets and downstream pathways leading to toxicity to drive project to safer chemistry.

noriko.uchiyama@takeda.com

Notes: